Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 3/20 | 0.62 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.50 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | GGT1 | P19440 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27485334 | 0.88 | ELANE (0.55) | ELANEABCB1KDM4EKMT2AMEN1 | |
| SCHEMBL2763226 | 0.84 | KDM4E (0.71) | ELANEKDM4EKMT2AMEN1RECQL | |
| SCHEMBL29492632 | 0.84 | KDM4E (0.71) | ELANEKDM4EKMT2AMEN1RECQL | |
| SCHEMBL9630421 | 0.83 | ELANE (0.58) | ELANEABCB1KDM4EKMT2AMEN1 | |
| SCHEMBL1913904 | 0.83 | SLC6A3 (0.56) | ELANEKDM4EKMT2AMEN1RECQL | |
| SCHEMBL5308300 | 0.82 | KDM4E (0.72) | ELANEKDM4EHSD17B10HPGDALDH1A1 | |
| SCHEMBL9066067 | 0.82 | MEN1 (0.68) | ELANEABCB1KDM4EKMT2AMEN1 | |
| SCHEMBL11035026 | 0.82 | ELANE (0.52) | ELANEKMT2AALDH1A1MAPTPAX8 | |
| SCHEMBL2229664 | 0.82 | ELANE (0.50) | ELANEKDM4EKMT2AMEN1RECQL | |
| SCHEMBL825435 | 0.81 | ELANE (0.56) | ELANEABCB1KDM4EKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024197483-A1 | METHOD FOR SYNTHESIZING DEXKETOPROFEN | 浙江九洲药业股份有限公司 | 2024-10-03 | — | — | WO | disclosed |
| WO-2024197480-A1 | METHOD FOR SYNTHESIZING DEXKETOPROFEN BY USING AMIDASE | 浙江九洲药业股份有限公司 | 2024-10-03 | — | — | WO | disclosed |
| CN-116334151-A | Method for synthesizing dexketoprofen | 浙江九洲药业股份有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-116121310-A | Method for synthesizing dexketoprofen by amidase | 浙江九洲药业股份有限公司 | 2023-05-16 | — | — | CN | disclosed |
| US-9717692-B2 | Effervescent formulations comprising dexketoprofen | BILGIC MAHMUT (TR) | 2017-08-01 | — | — | US | disclosed |
| EP-2709587-A2 | WATER-SOLUBLE FORMULATIONS COMPRISING DEXKETOPROFEN | Bilgic, Mahmut (TR) | 2014-03-26 | — | — | EP | disclosed |
| US-20140030326-A1 | EFFERVESCENT FORMULATIONS COMPRISING DEXKETOPROFEN | MAHMUT BILGIC (TR) | 2014-01-30 | — | — | US | disclosed |
| WO-2012158127-A2 | WATER-SOLUBLE FORMULATIONS COMPRISING DEXKETOPROFEN | BILGIC MAHMUT (TR) | 2012-11-22 | — | — | WO | disclosed |
| US-20110098284-A1 | Methods and compositions for treating pain | THERAQUEST BIOSCIENCES, LLC | 2011-04-28 | — | — | US | disclosed |
| CN-1162389-C | Prepn of 2-(3-benzoylphenyl) propionic acid enantiomer | 中国科学院上海有机化学研究所 | 2004-08-18 | — | — | CN | disclosed |
| US-6069172-A | ADMINISTERING THE ENANTIOMER (R)-KETOPROFEN AND OF ITS SALTS WITH SUITABLE ORGANIC AND INORGANIC BASES IN THE THERAPY OF NEUTROPHIL-DEPENDENT DISEASES | DOMPE' SPA (IT) | 2000-05-30 | — | — | US | disclosed |
| EP-0759899-B1 | NITRO COMPOUNDS AND THEIR COMPOSITIONS HAVING ANTI-INFLAMMATORY, ANALGESIC AND ANTI-THROMBOTIC ACITIVITIES | NICOX SA (FR) | 1999-09-15 | — | — | EP | disclosed |
| US-5861426-A | NITRO ESTERS OF AROMATIC COMPOUNDS WITH AMIDE OR ESTER GROUPS | NICOX S.A. (FR) | 1999-01-19 | — | — | US | disclosed |
| US-5852209-A | Process for optically resolving 2-(3-benzoylphenyl) propionic acid | NAGASE & CO., LTD. (JP) | 1998-12-22 | — | — | US | disclosed |
| EP-0703212-A1 | Process for optically resolving 2-(3-benzoylphenyl) propionic acid | NAGASE & COMPANY, LTD. (JP) | 1996-03-27 | — | — | EP | disclosed |
| WO-1995030641-A1 | NITRO COMPOUNDS AND THEIR COMPOSITIONS HAVING ANTI-INFLAMMATORY, ANALGESIC AND ANTI-THROMBOTIC ACITIVITIES | NICOX S.A. (FR) | 1995-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140030326-A1 | EFFERVESCENT FORMULATIONS COMPRISING DEXKETOPROFEN | PTGES, FASTKD5, PTGES3 | ELANE 1485/4885ABCB1 1191/4885KDM4E 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.